1. Home
  2. UTHR vs TROW Comparison

UTHR vs TROW Comparison

Compare UTHR & TROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • TROW
  • Stock Information
  • Founded
  • UTHR 1996
  • TROW 1937
  • Country
  • UTHR United States
  • TROW United States
  • Employees
  • UTHR N/A
  • TROW N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • TROW Investment Bankers/Brokers/Service
  • Sector
  • UTHR Health Care
  • TROW Finance
  • Exchange
  • UTHR Nasdaq
  • TROW Nasdaq
  • Market Cap
  • UTHR 20.7B
  • TROW 23.8B
  • IPO Year
  • UTHR 1999
  • TROW N/A
  • Fundamental
  • Price
  • UTHR $448.47
  • TROW $105.77
  • Analyst Decision
  • UTHR Buy
  • TROW Hold
  • Analyst Count
  • UTHR 15
  • TROW 13
  • Target Price
  • UTHR $459.60
  • TROW $105.00
  • AVG Volume (30 Days)
  • UTHR 846.4K
  • TROW 1.4M
  • Earning Date
  • UTHR 10-29-2025
  • TROW 10-31-2025
  • Dividend Yield
  • UTHR N/A
  • TROW 4.79%
  • EPS Growth
  • UTHR 17.94
  • TROW 5.45
  • EPS
  • UTHR 25.63
  • TROW 8.93
  • Revenue
  • UTHR $3,077,800,000.00
  • TROW $7,097,300,000.00
  • Revenue This Year
  • UTHR $13.71
  • TROW $4.25
  • Revenue Next Year
  • UTHR $5.72
  • TROW $5.27
  • P/E Ratio
  • UTHR $17.38
  • TROW $11.87
  • Revenue Growth
  • UTHR 17.62
  • TROW 4.43
  • 52 Week Low
  • UTHR $266.98
  • TROW $77.85
  • 52 Week High
  • UTHR $459.48
  • TROW $125.81
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 65.25
  • TROW 53.93
  • Support Level
  • UTHR $415.00
  • TROW $100.67
  • Resistance Level
  • UTHR $459.40
  • TROW $107.63
  • Average True Range (ATR)
  • UTHR 13.47
  • TROW 1.70
  • MACD
  • UTHR -1.34
  • TROW 0.33
  • Stochastic Oscillator
  • UTHR 71.49
  • TROW 73.22

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About TROW T. Rowe Price Group Inc.

T. Rowe Price provides asset management services for individual and institutional investors. It offers a broad range of no-load US and international stock, hybrid, bond, and money market funds. At the end of July 2025, the firm had $1.703 trillion in managed assets, composed of equity (50%), balanced (35%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a US-based asset manager, deriving less than 10% of its AUM from overseas.

Share on Social Networks: